Literature DB >> 22889334

A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma.

Karin Wadt1, Jiyeon Choi, Joon-Yong Chung, Jens Kiilgaard, Steffen Heegaard, Krzysztof T Drzewiecki, Jeffrey M Trent, Stephen M Hewitt, Nicholas K Hayward, Anne-Marie Gerdes, Kevin M Brown.   

Abstract

Inactivating germ line BRCA1-associated protein-1 (BAP1) mutations have recently been reported in families with uveal or cutaneous malignant melanoma (UMM, CMM), mesothelioma, and meningioma. Although apparently predisposing to a wide range of tumors, the exact tumor spectrum associated with germ line BAP1 mutations has yet to be established. Here, we report a novel germ line BAP1 splice mutation, c.1708C>G (p.Leu570fs*40), in a multiple-case Danish UMM family with a spectrum of other tumors. Whole-exome sequencing identified an apparent missense mutation of BAP1 in UMM, CMM, as well as paraganglioma, breast cancer, and suspected mesothelioma cases in the family. Bioinformatic analysis and splicing assays demonstrated that this mutation creates a strong cryptic splice donor, resulting in aberrant splicing and a truncating frameshift of the BAP1 transcript. Somatic loss of the wild-type allele was also confirmed in the UMM and paraganglioma tumors. Our findings further support BAP1 as a melanoma susceptibility gene and extend the potential predisposition spectrum to paraganglioma. 2012 John Wiley & Sons A/S. Published 2012. This article is a US Government work and is in the public domain in the USA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22889334      PMCID: PMC7453745          DOI: 10.1111/pcmr.12006

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  8 in total

1.  Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers.

Authors:  Mohamed H Abdel-Rahman; Robert Pilarski; Colleen M Cebulla; James B Massengill; Benjamin N Christopher; Getachew Boru; Peter Hovland; Frederick H Davidorf
Journal:  J Med Genet       Date:  2011-09-22       Impact factor: 6.318

2.  Frequent mutation of BAP1 in metastasizing uveal melanomas.

Authors:  J William Harbour; Michael D Onken; Elisha D O Roberson; Shenghui Duan; Li Cao; Lori A Worley; M Laurin Council; Katie A Matatall; Cynthia Helms; Anne M Bowcock
Journal:  Science       Date:  2010-11-04       Impact factor: 47.728

3.  a clinicopathologic report of 54 cases.

Authors:  R L Font; A G Spaulding
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1968 Nov-Dec

4.  Automated splicing mutation analysis by information theory.

Authors:  Vijay K Nalla; Peter K Rogan
Journal:  Hum Mutat       Date:  2005-04       Impact factor: 4.878

5.  Information analysis of human splice site mutations.

Authors:  P K Rogan; B M Faux; T D Schneider
Journal:  Hum Mutat       Date:  1998       Impact factor: 4.878

6.  Germline mutations in BAP1 predispose to melanocytic tumors.

Authors:  Thomas Wiesner; Anna C Obenauf; Rajmohan Murali; Isabella Fried; Klaus G Griewank; Peter Ulz; Christian Windpassinger; Werner Wackernagel; Shea Loy; Ingrid Wolf; Agnes Viale; Alex E Lash; Mono Pirun; Nicholas D Socci; Arno Rütten; Gabriele Palmedo; David Abramson; Kenneth Offit; Arthur Ott; Jürgen C Becker; Lorenzo Cerroni; Heinz Kutzner; Boris C Bastian; Michael R Speicher
Journal:  Nat Genet       Date:  2011-08-28       Impact factor: 38.330

7.  Germline BAP1 mutations predispose to malignant mesothelioma.

Authors:  Joseph R Testa; Mitchell Cheung; Jianming Pei; Jennifer E Below; Yinfei Tan; Eleonora Sementino; Nancy J Cox; A Umran Dogan; Harvey I Pass; Sandra Trusa; Mary Hesdorffer; Masaki Nasu; Amy Powers; Zeyana Rivera; Sabahattin Comertpay; Mika Tanji; Giovanni Gaudino; Haining Yang; Michele Carbone
Journal:  Nat Genet       Date:  2011-08-28       Impact factor: 38.330

8.  Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families.

Authors:  Ching-Ni Jenny Njauw; Ivana Kim; Adriano Piris; Michele Gabree; Michael Taylor; Anne Marie Lane; Margaret M DeAngelis; Evangelos Gragoudas; Lyn M Duncan; Hensin Tsao
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

  8 in total
  50 in total

Review 1.  The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.

Authors:  Lili Liao; Joseph R Testa; Haifeng Yang
Journal:  Cancer Genet       Date:  2015-02-20

2.  Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.

Authors:  Marjorie G Zauderer; Matthew Bott; Robert McMillan; Camelia S Sima; Valerie Rusch; Lee M Krug; Marc Ladanyi
Journal:  J Thorac Oncol       Date:  2013-11       Impact factor: 15.609

3.  Germline RAD51B truncating mutation in a family with cutaneous melanoma.

Authors:  Karin A W Wadt; Lauren G Aoude; Lisa Golmard; Thomas V O Hansen; Xavier Sastre-Garau; Nicholas K Hayward; Anne-Marie Gerdes
Journal:  Fam Cancer       Date:  2015-06       Impact factor: 2.375

4.  Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.

Authors:  Peter A Johansson; Vaishnavi Nathan; Lauren M Bourke; Jane M Palmer; Tongwu Zhang; Judith Symmons; Madeleine Howlie; Ann-Marie Patch; Jazlyn Read; Elizabeth A Holland; Helen Schmid; Sunil Warrier; William Glasson; Veronica Höiom; Karin Wadt; Göran Jönsson; Håkan Olsson; Christian Ingvar; Graham Mann; Kevin M Brown; Nicholas K Hayward; Antonia L Pritchard
Journal:  Melanoma Res       Date:  2019-10       Impact factor: 3.599

Review 5.  Update in genetic susceptibility in melanoma.

Authors:  Miriam Potrony; Celia Badenas; Paula Aguilera; Joan Anton Puig-Butille; Cristina Carrera; Josep Malvehy; Susana Puig
Journal:  Ann Transl Med       Date:  2015-09

Review 6.  Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment.

Authors:  Victoria L Martucci; Karel Pacak
Journal:  Curr Probl Cancer       Date:  2014-01-15       Impact factor: 3.187

7.  Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma.

Authors:  Jinfei Xu; Yuwaraj Kadariya; Mitchell Cheung; Jianming Pei; Jacqueline Talarchek; Eleonora Sementino; Yinfei Tan; Craig W Menges; Kathy Q Cai; Samuel Litwin; Hongzhuang Peng; Jayashree Karar; Frank J Rauscher; Joseph R Testa
Journal:  Cancer Res       Date:  2014-06-13       Impact factor: 12.701

8.  Molecular and translational advances in meningiomas.

Authors:  Suganth Suppiah; Farshad Nassiri; Wenya Linda Bi; Ian F Dunn; Clemens Oliver Hanemann; Craig M Horbinski; Rintaro Hashizume; Charles David James; Christian Mawrin; Houtan Noushmehr; Arie Perry; Felix Sahm; Andrew Sloan; Andreas Von Deimling; Patrick Y Wen; Kenneth Aldape; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

Review 9.  A Systematic Literature Review of Whole Exome and Genome Sequencing Population Studies of Genetic Susceptibility to Cancer.

Authors:  Alisa M Goldstein; Elizabeth M Gillanders; Melissa Rotunno; Rolando Barajas; Mindy Clyne; Elise Hoover; Naoko I Simonds; Tram Kim Lam; Leah E Mechanic
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-05-28       Impact factor: 4.254

Review 10.  Connecting molecular pathways to hereditary cancer risk syndromes.

Authors:  Joseph R Testa; David Malkin; Joshua D Schiffman
Journal:  Am Soc Clin Oncol Educ Book       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.